Your browser doesn't support javascript.
loading
Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015-2018.
Stahler, Gerald J; Mennis, Jeremy; Stein, L A R; Belenko, Steven; Rohsenow, Damaris J; Grunwald, Heidi E; Brinkley-Rubinstein, Lauren; Martin, Rosemarie A.
Afiliação
  • Stahler GJ; Department of Geography and Urban Studies, Temple University, United States. Electronic address: jstahler@temple.edu.
  • Mennis J; Department of Geography and Urban Studies, Temple University, United States.
  • Stein LAR; Center for Alcohol & Addiction Studies, Brown University School of Public Health, United States; Department of Psychology, The University of Rhode Island, United States.
  • Belenko S; Department of Criminal Justice, Temple University, United States.
  • Rohsenow DJ; Center for Alcohol & Addiction Studies, Brown University School of Public Health, United States.
  • Grunwald HE; Institute for Survey Research, Temple University, United States.
  • Brinkley-Rubinstein L; Department of Social Medicine, University of North Carolina at Chapel Hill, United States.
  • Martin RA; Center for Alcohol & Addiction Studies, Brown University School of Public Health, United States.
Drug Alcohol Depend ; 236: 109498, 2022 07 01.
Article em En | MEDLINE | ID: mdl-35605535
AIMS: To examine the use and association of medications for opioid use disorder (MOUD) with treatment completion and retention for criminal justice referred (CJR) admissions to residential treatment. METHODS: A retrospective analysis of the Treatment Episode Dataset-Discharge (TEDS-D; 2015-2018) for adults (N = 205,348) admitted to short-term (ST) (< 30 days) or long-term (LT) (>30 days) residential treatment for OUD. Outcomes were MOUD in treatment plans, and treatment completion and retention (ST >10 days; LT > 90 days). Logistic regression analyses were conducted separately for ST and LT settings. RESULTS: CJR admissions were less likely to have MOUD than non-CJR admissions (ST, 11% vs. 21%; LT, 10% vs. 24%, respectively) and were more likely to complete and be retained in treatment. In ST settings, MOUD was associated with higher likelihood of treatment completion and retention. In LT settings, MOUD was associated with higher likelihood of treatment retention and lower likelihood of treatment completion. These associations tended to be slightly weaker for CJR admissions, with the exception of treatment completion in LT settings, but the moderating effect size of CJR status in all models was very small. Small differences in the moderating effect of CJR status by race and ethnicity were observed in LT settings. CONCLUSIONS: MOUD is greatly under-utilized for CJR patients, and given that MOUD was associated with positive outcomes, there is a critical need to find ways to increase access to MOUD for CJR patients in residential treatment. Race and ethnicity appear to have relatively little impact on outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Drug Alcohol Depend Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Drug Alcohol Depend Ano de publicação: 2022 Tipo de documento: Article